Skip to main content

Table 1 Baseline patient characteristics in the unmatched and propensity-matched groups

From: The effect of antithrombin added to recombinant human-soluble thrombomodulin for severe community-acquired pneumonia-associated disseminated intravascular coagulation: a retrospective cohort study using a nationwide inpatient database

 

Unmatched group

Propensity-matched group

rhTM+AT

rhTM

SMD

rhTM+AT

rhTM

SMD

n = 253

n = 409

n = 189

n = 189

Age, mean (SD)

71.7 (13.6)

73.6 (13.5)

0.134

71.2 (14.0)

72.0 (14.2)

0.057

Sex (male), n (%)

86 (34.0)

125 (30.6)

0.073

59 (31.2)

60 (31.7)

0.011

Hospital type (academic), n (%)

100 (39.5)

89 (21.8)

0.393

65 (34.4)

62 (32.8)

0.034

Hospital volume (cases/year), mean (SD)

120.1 (46.5)

106.4 (57.3)

0.263

113.1 (42.7)

114.9 (57.5)

0.035

ICU admission, n (%)

76 (30.0)

114 (27.9)

0.048

64 (33.9)

58 (30.7)

0.068

HCU admission, n (%)

19 (7.5)

24 (5.9)

0.066

15 (7.9)

15 (7.9)

< 0.001

Comorbidity, n (%)

 Congestive heart failure

26 (10.3)

57 (13.9)

0.112

21 (11.1)

20 (10.6)

0.017

 Peripheral vascular disease

3 (1.2)

7 (1.7)

0.044

3 (1.6)

3 (1.6)

< 0.001

 Cerebrovascular disease

12 (4.7)

20 (4.9)

0.007

9 (4.8)

7 (3.7)

0.053

 Dementia

6 (2.4)

9 (2.2)

0.011

4 (2.1)

6 (2.1)

< 0.001

 Chronic pulmonary disease

13 (5.1)

26 (6.4)

0.052

11 (5.8)

12 (6.3)

0.022

 Rheumatologic disease

8 (3.2)

10 (2.4)

0.043

4 (2.1)

5 (2.6)

0.035

 Peptic ulcer

6 (2.4)

10 (2.4)

0.005

6 (3.2)

5 (2.6)

0.031

 Mild liver disease

9 (3.6)

15 (3.7)

0.006

6 (3.2)

7 (3.7)

0.029

 Diabetes without chronic complications

27 (10.7)

43 (10.5)

0.005

21 (11.1)

20 (10.6)

0.017

 Diabetes with chronic complications

8 (3.2)

14 (3.4)

0.015

8 (4.2)

8 (4.2)

< 0.001

 Renal disease

20 (7.9)

28 (6.8)

0.041

17 (9.0)

15 (7.9)

0.038

Consciousness level, n (%)

      

 Alert

80 (31.6)

192 (46.9)

0.318

73 (38.6)

68 (36.0)

0.055

 Delirium

71 (28.1)

83 (20.3)

0.182

49 (25.9)

53 (28.0)

0.048

 Somnolence

47 (18.6)

47 (11.5)

0.199

26 (13.8)

24 (12.7)

0.031

 Coma

52 (20.6)

70 (17.1)

0.088

38 (20.1)

40 (21.2)

0.026

Intervention, n (%)

 Mechanical ventilation

203 (80.2)

268 (65.5)

0.336

144 (76.2)

141 (74.6)

0.037

 Intermittent renal replacement therapy

62 (24.5)

53 (13.0)

0.299

37 (19.6)

41 (21.7)

0.052

 Continuous renal replacement therapy

10 (4.0)

11 (2.7)

0.071

7 (3.7)

6 (3.2)

0.029

 Polymyxin B hemoperfusion

43 (17.0)

39 (9.5)

0.221

24 (12.7)

27 (14.3)

0.046

 Bacterial culture collection

244 (96.4)

382 (93.4)

0.139

180 (95.2)

179 (94.7)

0.024

 Bronchoscopy

20 (7.9)

16 (3.9)

0.17

12 (6.3)

12 (6.3)

< 0.001

Catecholamine, n (%)

 Noradrenaline

199 (78.7)

232 (56.7)

0.482

139 (73.5)

138 (73.0)

0.012

 Dopamine

99 (39.1)

213 (52.1)

0.262

80 (42.3)

84 (44.4)

0.043

Platelet transfusion, n (%)

30 (11.9)

32 (7.8)

0.136

20 (10.6)

18 (9.5)

0.035

Fresh-frozen plasma transfusion, n (%)

28 (11.1)

15 (3.7)

0.286

10 (5.3)

14 (7.4)

0.087

Immunoglobulin, n (%)

136 (53.8)

125 (30.6)

0.483

91 (48.1)

85 (45.0)

0.064

Heparin, n (%)

209 (82.6)

242 (59.2)

0.534

148 (78.3)

152 (80.4)

0.052

Danaparoid, n (%)

5 (2.0)

8 (2.0)

0.001

5 (2.6)

4 (2.1)

0.035

Sivelestat sodium, n (%)

81 (32.0)

101 (24.7)

0.163

61 (32.3)

62 (32.8)

0.011

Low-molecular-weight heparin, n (%)

7 (2.8)

7 (1.7)

0.071

6 (3.2)

5 (2.6)

0.031

Hydrocortisone, n (%)

73 (28.9)

82 (20.0)

0.206

44 (23.3)

52 (27.5)

0.097

Initial antibiotic use, n (%)

 Ampicillin

5 (2.0)

5 (1.2)

0.06

4 (2.1)

2 (1.1)

0.085

 Ampicillin/sulbactam

29 (11.5)

52 (12.7)

0.038

25 (13.2)

26 (13.8)

0.015

 Piperacillin/tazobactam

48 (19.0)

76 (18.6)

0.01

37 (19.6)

37 (19.6)

< 0.001

 First-generation cephalosporin

3 (1.2)

2 (0.5)

0.077

2 (1.1)

2 (1.1)

< 0.001

 Third-generation cephalosporin without effect for Pseudomonas aeruginosa

38 (15.0)

55 (13.4)

0.045

30 (15.9)

24 (12.7)

0.091

 Fourth-generation cephalosporin

6 (2.4)

14 (3.4)

0.063

5 (2.6)

4 (2.1)

0.035

 Carbapenem

164 (64.8)

262 (64.1)

0.016

119 (63.0)

116 (61.4)

0.033

 Aminoglycoside

5 (2.0)

5 (1.2)

0.06

4 (2.1)

2 (1.1)

0.085

 Fluoroquinolone

68 (26.9)

103 (25.2)

0.039

49 (25.9)

54 (28.6)

0.059

 Macrolide

43 (17.0)

54 (13.2)

0.106

30 (15.9)

24 (12.7)

0.044

 Tetracycline

7 (2.8)

30 (7.3)

0.21

7 (3.7)

5 (2.6)

0.06

 Clindamycin

12 (4.7)

20 (4.9)

0.007

8 (4.2)

11 (5.8)

0.073

 Anti-MRSA drug

43 (17.0)

44 (10.8)

0.181

23 (12.2)

22 (11.6)

0.016

 Antifungal drug

5 (2.0)

5 (1.2)

0.06

4 (2.1)

4 (2.1)

< 0.001

  1. Abbreviations: rhTM recombinant human-soluble thrombomodulin, AT antithrombin, SMD standardized mean difference, SD standard deviation, ICU intensive care unit, HCU high care unit, MRSA methicillin-resistant Staphylococcus aureus